SCHEMBL513366

SCHEMBL513366

CCC(CC)(c1noc(-c2cccc(OC)c2)n1)P(=O)(O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.52
NPC1 O15118 8/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
TP53 P04637 3/20 0.52
NFKB1 P19838 2/20 0.52
NFKB2 Q00653 2/20 0.52
RELA Q04206 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALDH1A1 P00352 2/20 0.47
PKM P14618 1/20 0.46
GRM5 P41594 1/20 0.46
MAPK1 P28482 1/20 0.46
HAVCR2 Q8TDQ0 4/20 0.46
POLB P06746 1/20 0.46
PIK3CD O00329 1/20 0.46
PIK3CB P42338 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513092 0.85 NPC1 (0.46) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL513589 0.84 NPC1 (0.47) RAB9ANPC1SMN1; SMN2TP53NFKB1
SCHEMBL513254 0.84 TP53 (0.45) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL513204 0.83 HDAC6 (0.44) RAB9ANPC1SMN1; SMN2TP53NFKB1
SCHEMBL512771 0.82 RAB9A (0.49) RAB9ANPC1SMN1; SMN2TDP1ALDH1A1
SCHEMBL513221 0.78 CHRNB2 (0.49) RAB9ANPC1SMN1; SMN2TP53NFKB1
SCHEMBL513425 0.77 NPC1 (0.45) RAB9ANPC1SMN1; SMN2TP53NFKB1
SCHEMBL512093 0.75 NPC1 (0.41) RAB9ANPC1SMN1; SMN2TP53NFKB1
SCHEMBL512821 0.74 CA2 (0.41) RAB9ANPC1TDP1ALDH1A1POLB
SCHEMBL513461 0.74 CCR1 (0.37) RAB9ANPC1SMN1; SMN2TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 RAB9A 2058/4885NPC1 4017/4885SMN1; SMN2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.